RxDoctor Payments Data

Sneh Dhannawat, MD

Ophthalmology · Baltimore, MDNPI 1124434063

Payments from drug & device makers

$3,645in general payments, 2019–2025

Across 125 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$908
  • Glaukos Corporation$493
  • Alcon$491
  • Sun Pharmaceutical Industries Inc.$359
  • Oyster Point Pharma, Inc.$332
  • Sight Sciences, Inc.$204
  • plus $858 from 14 others

What the payments were for

  • Food & beverage$3,645100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,645 in reported general payments places this provider in the 70th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$432,505
Medicare patients
1,312
Services billed
3,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost37$28,427
RocklatanNetarsudil Mesylat/Latanoprost20$12,931
Cyclosporine15$12,883
CombiganBrimonidine Tartrate/Timolol25$12,631
VyzultaLatanoprostene Bunod17$9,895
Latanoprost465$8,622
TyrvayaVarenicline Tartrate13$8,610
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat280$5,848
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$5,827
Timolol Maleate86$5,125
Tobramycin-DexamethasoneTobramycin/Dexamethasone65$3,194
Prednisolone Acetate79$3,096
TobradexTobramycin/Dexamethasone11$2,857
SimbrinzaBrinzolamide/Brimonidine Tart11$2,839
Travoprost15$2,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$908$41,05862 claims
Aerie Pharmaceuticals, Inc.Rocklatan$16$12,93120 claims
Bausch & Lomb Americas Inc.Vyzulta$157$9,89517 claims
Oyster Point Pharma, Inc.Tyrvaya$332$8,61013 claims
AlconSimbrinza$491$2,83911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →